Aradigm Corporation (OTC BB: ARDM), an emerging specialty pharmaceutical company, is committed to developing and commercializing a portfolio of drugs designed to treat severe respiratory diseases. With its clinical expertise, targeted development efforts, and strength of a well accomplished leadership team, the company is poised to capitalize on niche opportunities for new and improved products used in the treatment of severe respiratory disease. For further information, visit the Company’s web site at www.aradigm.com.
- 17 years ago
QualityStocks
Aradigm Corporation (OTC BB: ARDM)
Related Post
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Reports Q3 2025 Net Income of $1.5 Million and 42% Gross Margin, Highlighting Strong Operational Turnaround
Massimo Group (NASDAQ: MAMO), a provider of powersports vehicles and related equipment, reported revenue of…
-
QualityStocksNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Completes Montauban Mill Building, Moves Toward Commissioning and First Gold-Silver Production in 2026
This article has been disseminated on behalf of ESGold Corp. and may include paid advertising. ESGold…
-
QualityStocksNewsBreaks – D-Wave (NYSE: QBTS) Advantage2TM Quantum Computer Now Available for U.S. Government Applications at Davidson Technologies
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a global leader in quantum computing systems, software and…